• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Photodiagnosis and Photodynamic Therapy >Anthraquinone encapsulation into polymeric nanocapsules as a new drug from biotechnological origin designed for photodynamic therapy
【24h】

Anthraquinone encapsulation into polymeric nanocapsules as a new drug from biotechnological origin designed for photodynamic therapy

机译：Anthraquinone将聚合物纳米胶囊封装为来自设计用于光动力疗法的生物技术来源的新药

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Photodynamic therapy has been applied for the treatment of many diseases, especially skin diseases. However, poor aqueous solubility and toxicity of some photosensitizer drugs are the main disadvantages for their direct clinical applications. Thus, biotechnology and nanotechnology are important tools in the development of new ways of obtaining photoactive compounds that are biocompatible. We investigated the potential of a new nanostructured photosensitizer, an anthraquinone derivative produced by biotechnological process; then we associated nanotechnology to obtain a nanostructured anthraquinone active molecule. For this, it was prepared a classical nanocapsule formulations containing poly(lactide-co-glycolide) (PLGA) coating for encapsulation of anthraquinone derivative. These formulations were characterized by their physicochemical, morphological, photophysical properties, and stability. We performed in vitro biocompatibility and photodynamic activity assays of free and nanostructured anthraquinone. Nanocapsule formulations containing anthraquinone derivative showed a nanometric profile with particle size around 250 nm, negative zeta potential around - 30 mV, and partially monodisperse. Besides that, characteristic spherical morphology of nanocapsules and homogeneous particle surface were observed by AFM analyses. The in vitro biocompatibility assay showed absence of cytotoxicity for all tested RD/NC concentrations and also for unloaded/NC in NIH3T3 cells. In vitro photoactivation assay using NIH3T3 cells showed that nanocapsules promoted greater drug uptake by NIH3T3 cells, around of 87%, of cell death compared to free drug showed around 48% of cell death. The anthraquinone derivative showed potential for use in PDT. Besides the association with nanocapsules improved cell uptake of photosensitizer resulting in increased cell death compared to free anthraquinone.
机译：光动力疗法已被应用于治疗许多疾病，特别是皮肤病。然而，一些光敏剂药物的差的含水溶解度和毒性是其直接临床应用的主要缺点。因此，生物技术和纳米技术是在获得生物相容性的光活性化合物的新方法开发的重要工具。我们调查了一种新的纳米结构光敏剂，一种由生物技术过程产生的Anthraquinone衍生物的潜力;然后我们相关的纳米技术以获得纳米结构的蒽醌活性分子。为此，制备了含有聚（丙交酯 - 共乙酰基）（PLGA）涂层的经典纳米胶囊制剂，用于包封蒽醌衍生物。这些制剂的特征在于它们的物理化学，形态学，光学性质和稳定性。我们在体外的生物相容性和光动力学活性测定的自由和纳米结构的蒽醌进行。含有蒽醌衍生物的纳米胶囊制剂显示颗粒尺寸约为250nm，阴性ζ电位约为30mV，部分单分散的纳米曲线。此外，通过AFM分析观察纳米胶囊和均相颗粒表面的特征球形形态。体外生物相容性测定显示出对所有测试的RD / NC浓度的细胞毒性以及在NIH3T3细胞中的卸载/ Nc。使用NiH3T3细胞的体外光活激活测定显示，与游离药物相比，纳米胶囊促进NIH3T3细胞的更多药物吸收，约87％的细胞死亡显示48％的细胞死亡。 Anthraquinone衍生物显示出PDT的潜力。除了与纳米胶囊相关的关联，与游离蒽醌相比，相比，光敏剂的细胞吸收导致细胞死亡增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号